CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo attack on HPV-Linked throat cancer
Disease control OngoingThis study is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a targeted course of radiation is safe and effective for treating advanced throat cancer caused by HPV. The goal is to help the body's immune system better recognize and attack the can…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 04:05 UTC
-
Could a lower radiation dose beat throat cancer with fewer side effects?
Disease control OngoingThis study is testing if a lower dose of radiation combined with an immunotherapy drug (nivolumab) works as well as the standard, higher-dose radiation combined with chemotherapy (cisplatin) for treating early-stage throat cancer linked to HPV in non-smokers. The goal is to contr…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Can a year of Immune-Boosting drug keep throat cancer from coming back?
Disease control OngoingThis study is for people with intermediate-risk, HPV-positive throat cancer that has spread to nearby lymph nodes. After finishing standard treatment with chemotherapy and radiation, patients are randomly assigned to either receive a year of an immunotherapy drug (nivolumab) or t…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC